Iga Swiatek, the five-time Grand Slam winner, revealed that she “scared” the public’s reaction following her doping suspension. The 23-year-old Polish star tested positive for trimetazidine (TMZ), a heart medication, in August while ranked world number one. However, the International Tennis Integrity Agency (ITIA) accepted Swiatek’s explanation that contamination caused the positive test, and her brief suspension ended on December 4.
Swiatek was not the only top player who experienced the effects of doping issues this year. Men’s world number one Jannik Sinner also faced scrutiny after failing two tests in March. Although he did not receive a ban, the World Anti-Doping Agency (WADA) has appealed the decision. However, Swiatek does not foresee a similar outcome for her case.
“I was suspended for a long time and lost my world number one ranking because of it,” Swiatek said. “I gave all the evidence I could, and I don’t think there is anything more I can do. So, I’m not expecting an appeal, but I have no control over what happens next.”
The ITIA confirmed that Swiatek’s positive test was due to contamination from melatonin, a non-prescription medication that Swiatek had used to manage jet lag and sleep issues. The ITIA determined that Swiatek’s level of fault was minimal, categorizing it as the lowest range of ‘no significant fault or negligence’. As a result, she missed three tournaments—the Korea Open, China Open, and Wuhan Open—during her suspension and forfeited her prize money from the Cincinnati Open, the event following her test.
In her first public comments on the suspension, made before the United Cup in Australia, Swiatek expressed her concerns about how others would receive the situation. “I was scared people might turn their back on me,” she admitted. “But the response has been more positive than I expected. Most people who understand how the system works know I had no fault and no influence over what happened. In Poland, the reaction has been overwhelmingly supportive, and I really appreciate that.”
Swiatek acknowledged that some negative comments were inevitable but said she had learned to ignore them.
Meanwhile, Sinner, who faces a potential suspension for a positive test for the anabolic steroid clostebol, is still awaiting the outcome of WADA’s appeal to the Court of Arbitration for Sport (CAS).
Both Swiatek and Sinner will begin the 2024 season among the favorites for the Australian Open, which starts on January 12 in Melbourne. Swiatek, who has never gone beyond the semifinals in Melbourne, will aim to improve on her third-round exit at the 2024 tournament, where Linda Noskova defeated her.
Leave a Reply